Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with KRAS p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial. Read More ›
The number of cancer survivors continues to increase in the United States, which can be attributed to a growing and aging population, as well as recent advances in diagnosis and treatment. Read More ›
The use of a polygenic score (PGS) based on noncancer genetic variations in prostate-specific antigen (PSA) values helped to refine PSA screening in a large group of men without prostate cancer at baseline.
Read More ›